PDF herunterladen
CC BY-NC-ND 4.0 · J Neurol Surg Rep 2019; 80(02): e23-e26
DOI: 10.1055/s-0039-1687848
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Cesium-131 Interstitial Brachytherapy for Recurrent Malignancies of Skull Base

Corey Savard
1   Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
Gregory Epps
2   Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
Voichita Bar Ad
3   Department of Radiation Oncology–Head and Neck Cancer, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
Joseph Curry
2   Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
James J. Evans
4   Department of Neurosurgery–Neuro-Oncologic and Stereotactic Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
Christopher J. Farrell
4   Department of Neurosurgery–Neuro-Oncologic and Stereotactic Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
Gurston Nyquist
2   Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
,
Adam Luginbuhl
2   Department of Otolaryngology–Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
› Institutsangaben
Weitere Informationen

Publikationsverlauf

20. Dezember 2018

20. Februar 2019

Publikationsdatum:
09. April 2019 (online)

   Lizenzen und Reprints

Abstract

Background Recurrent malignancy of the skull base poses a treatment challenge due to a lack of treatment options and potential for damage to surrounding structures.

Methods Case report of two patients with recurrent nasopharyngeal carcinoma (NPC) of skull base previously treated with adjuvant chemoradiotherapy using intensity-modulated radiation therapy (IMRT).

Results In both cases, the recurrent tumor was treated with endoscopic surgical resection and intraoperative cesium-131 (Cs-131) interstitial brachytherapy (IBT). Total dose delivered to tumor bed was 57 and 60 Gy, respectively. With a half- life of 9 days, the majority of the radiation dose had been delivered within the first 40 days following implant and there have been no treatment-related complications reported.

Conclusion Intraoperative Cs-131 IBT is a feasible adjuvant treatment option for patients with recurrent malignancies of the skull base. These are the first known cases of Cs-131 IBT used for recurrent NPC.

Keywords

cesium-131 - interstitial - brachytherapy - nasopharyngeal carcinoma - recurrent

Financial Disclosure

The authors have indicated they have no financial relationships relevant to this article to disclose.


 

  • References

  • 1 Kupferman ME, Morrison WH, Santillan AA. , et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer 2007; 109 (10) 2052-2057
    CrossrefPubMedGoogle Scholar
  • 2 Parashar B, Wernicke AG, Pavese A. , et al. Cesium-131 permanent seed brachytherapy: dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff. Brachytherapy 2011; 10 (06) 508-513
    CrossrefPubMedGoogle Scholar
  • 3 Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 2003; 55 (02) 378-385
    CrossrefPubMedGoogle Scholar